Advertisement

Topics

Tumor Necrosis Factor Receptor Superfamily Member 5 B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40 Pipeline Review, H2 2017 [Report Updated: 08082017] Prices from USD $3500

05:07 EDT 10 Aug 2017 | BioPortfolio Reports

Tumor Necrosis Factor Receptor Superfamily Member 5 B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40 Pipeline Review, H2 2017

Summary

According to the recently published report 'Tumor Necrosis Factor Receptor Superfamily Member 5 Pipeline Review, H2 2017'; Tumor Necrosis Factor Receptor Superfamily Member 5 B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40 pipeline Target constitutes close to 21 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes.

Tumor Necrosis Factor Receptor Superfamily Member 5 B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40 Tumor Necrosis Factor Receptor Superfamily Member 5 is a member of the TNFreceptor superfamily. This protein is a receptor on antigenpresenting cells of the immune system and is essential for mediating a broad variety of immune and inflammatory responses including T celldependent immunoglobulin class switching, memory B cell development, and germinal center formation. The interaction of this receptor and its ligand is found to be necessary for amyloidbetainduced microglial activation, and thus is thought to be an early event in Alzheimer disease pathogenesis.

The report 'Tumor Necrosis Factor Receptor Superfamily Member 5 Pipeline Review, H2 2017' outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 5 B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 5 B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40 targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 6, 4 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Gastrointestinal, Central Nervous System, Genito Urinary System And Sex Hormones, Hematological Disorders, Hormonal Disorders and Metabolic Disorders which include indications Solid Tumor, Crohn's Disease Regional Enteritis, Kidney Transplant Rejection, Lymphoma, Melanoma, NonSmall Cell Lung Cancer, Pancreatic Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Ovarian Cancer, Rheumatoid Arthritis, Adenocarcinoma Of The Gastroesophageal Junction, Bladder Cancer, Diffuse Large BCell Lymphoma, Follicular Lymphoma, Gastroesophageal GE Junction Carcinomas, Graves Diseases, Heart Transplant Rejection, Hepatocellular Carcinoma, Hodgkin Lymphoma BCell Hodgkin Lymphoma, Hyperthyroidism, Idiopathic Thrombocytopenic Purpura Immune Thrombocytopenic Purpura, Lupus Nephritis, Membranous Glomerulonephritis, Metastatic Adenocarcinoma of The Pancreas, Metastatic Melanoma, Metastatic Ovarian Cancer, Multiple Sclerosis, Myasthenia Gravis, Osteosarcoma, Pancreatic Islet Transplant Rejection, Primary Biliary Cirrhosis, Prostate Cancer, Renal Cell Carcinoma, Sicca Syndrome Sjogren, Type 1 Diabetes Juvenile Diabetes and Ulcerative Colitis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 5 B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40
The report reviews Tumor Necrosis Factor Receptor Superfamily Member 5 B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 5 B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40 targeted therapeutics and enlists all their major and minor projects
The report assesses Tumor Necrosis Factor Receptor Superfamily Member 5 B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 5 B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40 targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 5 B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 5 B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Tumor Necrosis Factor Receptor Superfamily Member 5 B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40 Pipeline Review, H2 2017 [Report Updated: 08082017] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Tumor Necrosis Factor Receptor Superfamily Member 5 B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40 Pipeline Review, H2 2017 [Report Updated: 08082017] Prices from USD $3500"

Quick Search
Advertisement
 

Relevant Topic

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...